The number of pharmaceutical industry-sponsored clinical trials has been declining since 2002, and the number of principal investigators running trials in the United States has been falling even faster, according to a study by the Tufts Center for the Study of Drug Development.
Using information from forms submitted to Food and Drug Administration (FDA) by principal investigators, researchers found that a “major expansion” of industry-sponsored research “levelled off” in 2000 and began declining after 2002. Study author Kenneth Getz, a research fellow at the Tufts CSDD, says the drop in research since 2002 is largely the result of cancellations of trials entering their final phase.
Furthermore:
Getz says clinical trials increasingly are being performed abroad in areas where costs are lower, such as Eastern Europe, South America and India.
Getz says that the big message here is that the decline in principal investigators is not solely a function of the short-term decline in clinical projects. If we continue to see this in the longer term, it could diminish the ability of pharmaceutical companies to innovate.
Source: Marc Kaufman, Clinical Trials of Drugs Fewer, Study Says; Report Also Notes Decline in Number of Principal Investigators in U.S., Washington Post, May 4, 2006.
For text (subscription required): http://www.washingtonpost.com/wp-dyn/content/article/2005/05/03/AR2005050301268.html
For more on Health: http://www.ncpa.org/iss/hea/
FMF Policy Bulletin 09 May 2006
